Aldea Pharmaceuticals Obtains $24,000,000 Series B Round

  • Feed Type
  • Date
    8/25/2014
  • Company Name
    Aldea Pharmaceuticals
  • Mailing Address
    3696 Haven Avenue Redwood City, CA 94063 USA
  • Company Description
    Aldea Pharmaceuticals is developing a number of small-molecule modulators of the aldehyde dehydrogenase enzyme (ALDH) superfamily. This proprietary scientific approach was originally discovered by Stanford University researchers and exclusively licensed to Aldea. With its ALDH platform, Aldea has the unique opportunity to pursue novel targets across multiple therapeutics areas to address significant unmet medical needs.
  • Website
    http://www.aldeapharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $24,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The financing will be used to advance Aldea’s lead drug candidate, AD-6626, into clinical trials, including evaluating proof-of-concept for the treatment of subjects with acute alcohol intoxication and funding subsequent Phase 2 trials of intravenous (IV) AD-6626 in an emergency room (ER) setting. In addition, Aldea is studying oral AD-6626 for the treatment of subjects with the rare genetic disease Fanconi anemia, and anticipates the financing will support a Phase 1/2 proof-of-biology study in that indication.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

By posting a comment, you agree to our terms and conditions.